Fractalkine/CX3CR1 and atherosclerosis

Clinica Chimica Acta

Volumn 412, Issue 13-14, 2011, Pages 1180-1186

  Liu, Hong ^a   Jiang, Deqian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Atherosclerosis; Fractalkine; Inflammation

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL INTERACTION; CELL PROLIFERATION; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM; HAPLOTYPE; HUMAN; INFLAMMATION; LEUKOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; BLOOD VESSELS; CHEMOKINE CX3CL1; HUMANS; POLYMORPHISM, GENETIC; UP-REGULATION;

MUS;

EID: 79955382689     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.036     Document Type: Review

References (68)

1. Weber C., Schober A., Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2000, 424(11):1997-2008.
2. Keane M.P., Strieter R.M. Chemokine signaling in inflammation. J Crit Care 2000, 28(4 Suppl.):N13-N26.
3. Bazan J.F., Bacon K.B., Hardiman G.J. A new class of membrane bound chemokine with a CX3C motif. Nature 1997, 385(6617):640-644.
4. Imai T., Hieshima K., Haskell C., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
5. Goda S., Imai T., Yoshie O., et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000, 164:4313-4320.
6. Umehara H., Bloom E., Okazaki T., Domae N., Imai T. Fractalkine and vascular injury. Trends Immunol 2001, 22:602-607.
7. Greaves D.R., Hakkinen T., Lucas A.D., et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001, 21:923-929.
8. Wong B.W., Wong D., McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002, 11:332-338.
9. Combadiere C., Potteaux S., Gao J.L., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003, 107:1009-1016.
10. Lesnik P., Haskell C.A., Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003, 111:333-340.
11. Saederup N., Chan L., Lira S.A., Charo I.F. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice. Evidence for independent chemokine functions in atherogenesis. Circulation 2007, 117(13):1642-1648.
12. Haskell C.A., Cleary M.D., Charo I.F. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000, 275(44):34183-34189.
13. Fong A.M., Erickson H.P., Zachariah J.P., et al. Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation. J Biol Chem 2000, 275(6):3781-3786.
14. Garton K.J., Gough P.J., Blobel C.P., et al. Tumor necrosis factor-alpha-converting enzyme(ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001, 276(41):37993-38001.
15. Mizoue L.S., Bazan J.F., Johnson E.C., Handel T.M. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 1999, 38(5):1402-1414.
16. Harrison J.K., Jiang Y., Chen S., Murphy P.M. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998, 95:10896-10901.
17. Lucas A.D., Chadwick N., Warren B.F., et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001, 158:855-866.
18. Papadopoulos E.J., Sassetti C., Saeki H., et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 1999, 29:2551-2559.
19. Ludwig A., Berkhout T., Moores K., Groot P., Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002, 168:604-612.
20. Garcia G.E., Xia Y., Chen S., et al. NF-κB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1β TNF-α, and LPS. J Leukoc Biol 2000, 67:577-584.
21. Landsman L., Bar-On L., Zernecke A., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009, 113(4):963-972.
22. Fraticelli P., Sironi M., Bianchi G., et al. Fractalkine(CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001, 107:1173-1181.
23. Apostolakis S., Krambovitis E., Vlata Z., Kochiadakis G.E., Baritaki S., Spandidos D.A. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thromb Res 2007, 121(3):387-395.
24. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003, 108:2498-2504.
25. Yang X.P., Jones R.A., Rivers J.H. Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak-Stat5 pathway. Circ Res 2007, 101(10):1001-1008.
26. Chandrasekar B., Mummidi S., Perla R.P., et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003, 373:547-558.
27. Ahn S.Y., Cho C.H., Park K.G., et al. Tumor necrosis factor-α induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-α-induced fractalkine expression. Am J Pathol 2004, 164:1663-1672.
28. Apostolakis S., Vlata Z., Vogiatzi K., Krambovitis E., Spandidos D.A. Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis. J Thromb Thrombolysis 2010, 29(4):443-448.
29. Popovic M., Laumonnier Y., Burysek L., Syrovets T., Simmet T. Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration. J Leukoc Biol 2008, 84(1):215-223.
30. Matsumiya T., Imaizumi T., Fujimoto K., et al. Soluble interleukin-6 receptor α inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 2001, 269:35-41.
31. Matsumiya T., Imaizumi T., Tamo W., et al. 15-Deoxy-△12,14-prostaglandin J2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol Cell Biol 2002, 80:531-536.
32. Barlic J., Zhang Y., Philip M.M. Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFα-NF-κB-dependent manner. J Biol Chem 2007, 282(26):19167-19176.
33. Cheng C. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006, 113:2744-2753.
34. Cheng C., Tempel D., van Haperen R., et al. Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. J Clin Invest 2007, 117(3):616-626.
35. Dragomir E., Manduteanu I., Calin M., et al. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost 2008, 100(6):1155-1165.
36. Meng L., Park J., Cai Q., Lanting L., Reddy M.A., Natarajan R. Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol 2010, 298(3):H736-H745.
37. Manduteanu I., Pirvulescu M., Gan A.M., et al. Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells. Biochem Biophys Res Commun 2010, 391(3):1443-1448.
38. Damas J.K., Boullier A., Waehre T., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005, 25:2567-2572.
39. Ikejima H., Imanishi T., Tsujioka H., et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010, 74(2):337-345.
40. McDermott D.H., Fong A.M., Yang Q., et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003, 111:1241-1246.
41. Moatti D., Faure S., Fumeron F., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001, 97:1925-1928.
42. Niessner A., Marculescu R., Haschemi A., et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. Thromb Haemost 2005, 93:949-954.
43. Niessner A., Marculescu R., Kvakan H., et al. Fractalkine receptor polymorphisms V249I and T280M as genetic risk factors for restenosis. Thromb Haemost 2005, 94:1251-1256.
44. Apostolakis S., Amanatidou V., Papadakis E.G., Spandidos D.A. Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009, 207(1):8-15.
45. Fong A.M., Robinson L.A., Steeber D.A., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188:1413-1419.
46. Kerfoot S.M., Lord S.E., Bell R.B., Gill V., Robbins S.M., Kubes P. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions: a mechanism for selective monocyte recruitment. Eur J Immunol 2003, 33:729-739.
47. Umehara H., Goda S., Imai T., Nagano Y., Minami Y., Tanaka Y. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol 2001, 79:298-302.
48. Haskell C.A., Cleary M.D., Charo I.F. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 1999, 274:10053-10058.
49. Green S.R., Han K.H., Chen Y., et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J Immunol 2006, 176(12):7412-7420.
50. Yoneda O., Imai T., Goda S., Inoue H., Yamauchi A., Okazaki T. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000, 164(8):4055-4062.
51. Foussat A., Coulomb-L'Hermine A., Gosling J., et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000, 30(1):87-97.
52. Dichmann S., Herouy Y., Purlis D., Rheinen H., Gebicke-Harter P., Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res 2001, 509(11):529-533.
53. Gevrey J.C., Isaac B.M., Cox D. Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 2005, 175(6):3737-3745.
54. Vitale S., Schmid-Alliana A., Breuil V., et al. Soluble fractalkine prevents monocyte chemoattractant protein-1-induced monocyte migration via inhibition of stress- activated protein kinase 2/p38 and matrix metalloproteinase activities. J Immunol 2004, 172(1):585-592.
55. Cambien B., Pomeranz M., Schmid-Antomarchi H., et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001, 97:2031-2037.
56. Volin M.V., Huynh N., Klosowska K., Reyes R.D., Woods J.M. Fractalkine-induced endothelial cell migration requires MAP kinase signaling. Pathobiology 2010, 77(1):7-16.
57. Geissmann F., Jung S., Littmann D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
58. Barlic J., Zhang Y., Foley J.F., Murphy P.M. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor {gamma}-dependent pathway. Circulation 2006, 114(8):807-819.
59. Kansra V., Groves C., Gutierrez Ramos J.C., Polakiewicz R.D. Phosphatidylinositol 3-kinase- dependent extracellular calcium influx is essential for CX(3)CR1-mediated activation of the mitogen-activated protein kinase cascade. J Biol Chem 2001, 276(34):31831-31838.
60. Nishimura M., Umehara H., Nakayama T., et al. Dual functions of fractalkine/CX3CR1 in trafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002, 138:6173-6180.
61. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
62. Massberg S., Brand K., Grüner S., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002, 196:887-896.
63. Huo Y., Schober A., Forlow B., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003, 9:61-67.
64. Schäfer A., Schulz C., Eigenthaler M., et al. Novel role of the membrane bound chemokine fractalkine in platelet activation and adhesion. Blood 2003, 103:407-412.
65. Schulz C., Schäfer A., Stolla M., et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007, 116(7):764-773.
66. White G.E., Tan T.C., John A.E., Whatling C., McPheat W.L., Greaves D.R. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010, 85(4):825-835.
67. Kumar A.H., Metharom P., Schmeckpeper J., Weiss S., Martin K., Caplice N.M. Bone marrow-derived CX3CR1 progenitors contribute to neointimal smooth muscle cells via fractalkine CX3CR1 interaction. FASEB J 2010, 24(1):81-92.
68. Volger O.L., Fledderus J.O., Kisters N., et al. Distinctive expression of chemokines and transforming growth factor-β signaling in human arterial endothelium during atherosclerosis. Am J Pathol 2007, 171(1):326-337.